leisure time -WSS

leisure time

author：explore 2025-09-30 23:06:10 - browse：473

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Neuroscience startup Neumora files for IPO

WSS

Covid hospitalizations on the rise, Humana says

The (many) problems with a new study criticizing cancer screening

Ethical issues complicate the benefits of medical crowdfunding

How to make Best Hospitals ratings actually useful for patients

FDA panel gives mixed vote on blood pressure devices

Radiation, mainstay of cancer treatment, begins a fade

entertainment

leisure time

hotspot

Sports medicine is finally prioritizing gender equality

How to protect patients from sexual assault

Tori Bowie and the unacceptable rates of Black maternal death

FDA panel gives mixed vote on blood pressure devices

Tori Bowie and the unacceptable rates of Black maternal death

What American doctors can learn from their Israeli counterparts

Drug repurposing or repositioning? The language matters

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

In age of alternative facts, a scholarly course on calling out crap

Trump surgeon general acknowledges mistakes during Covid

hotspot

Listen: Biogen's potential pivot, & Illumina's next chapter

CDC advisory panel says seniors 'may' get RSV vaccine

How Long Island became the ‘eugenics capital of the world’

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Apellis safety probe of eye disease drug centers on injection needle

Medicaid rebukes states for mistakenly disenrolling children

focus

hotspot

knowledge

explore